sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released Form 8.3 as per the requirements of the Irish Takeover Panel Act. This disclosure is concerning Avadel Pharmaceuticals plc, relating to relevant securities they hold a substantial interest in. As of December 8, 2025, Vanguard reported owning 5,583,006 ordinary shares, representing a 5.73% stake in Avadel.
Recent transactions included the purchase of 3,731 shares and the sale of 1,434 shares, both at a unit price of $21.32. No derivative transactions were reported in this disclosure. Furthermore, there are no relevant indemnity or option agreements or any arrangements with other parties concerning derivatives.
This transparency is part of the compliance with takeover regulations, ensuring full disclosure of significant holdings in Avadel Pharmaceuticals by investment firms.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.